The therapeutic strategy in early breast cancer (BC) is based on TNM staging and on primary tumor (PT) molecular subtype as defined by expression of hormone receptors (estrogen, ER, and progesterone, PR), HER2, and to a lesser extent by Ki67 expression level and genomic signatures [1]. The gene discussed is MKI67; the disease is breast cancer.